HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” NASDAQ: TARO) today announced that its Board of Directors presently expects to receive the report from the independent counsel retained by its Audit Committee to investigate the circumstances relating to the previously announced restatement of the Company’s 2003 and 2004 financial results by October 20, 2006.
